Analyst consensus rating
Parabilis Medicines Analyst Rating: Strong Buy
Direct answer
Parabilis Medicines's consensus rating is Strong Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $41.40.
Forecast evidence checked October 27, 2026.
Get free Parabilis Medicines email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $26.51
- Average price target
- $41.40
- High price target
- $45.00
- Low price target
- $40.00
- Low target gap
- +50.9%
- Target upside
- +56.2%
- High target gap
- +69.7%
- Target range width
- 18.9%
- Consensus rating
- Strong Buy
- Analysts
- 5
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Parabilis Medicines?
Parabilis Medicines has a verified Strong Buy consensus. The same dataset has an average price target of $41.40.
How far are Parabilis Medicines's low and high targets from the recorded price?
The low target implies +50.9%, while the high target implies +69.7%.
How many analysts are included in Parabilis Medicines's consensus?
The verified consensus includes 5 analysts.
How is Parabilis Medicines's target upside or downside calculated?
The average target of $41.40 is divided by the recorded price of $26.51, then one is subtracted to produce +56.2%. This does not guarantee a future return.
When was Parabilis Medicines's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.